Print

UBI V106

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

Trial Details:

I/II Completed
UBI November 01, 1999
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent Protein
USA 24
http://www.clinicaltrials.gov; http://www.actis.org